Global Hydraulic Press Machine Market to Witness 4.8% CAGR during 2017 - 2023     |   Global Auto-Injectors Market to Witness 18.6% CAGR during 2017 – 2023     |    Global Ammonium Phosphate Market to Witness 3.6% CAGR During 2016 – 2022

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

P&S Market Research - A market research firm

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline to Witness Increased R&D Investment in the Coming Years

 

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline to Witness Increased R&D Investment in the Coming Years

April 2017

According to a new research report “Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments” published by P&S Market Research, PI3K inhibitors currently exhibits a strong pipeline with approximately 37 drug candidates.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis 

PI3K inhibitors pipeline analysis

The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates, of which eight drug candidates are in Phase III stage, 10 drug candidates are in Phase II stage, nine drug candidates Phase I stage, eight in Pre-Clinical stage and two drug candidates are in Discovery stage.

Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is categorized on the basis of classes as class I, II and III, on the basis of structure of the PI3K, based on the specificities of the substrate as well as on the basis of lipid end-product’s nature. Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.

Pipeline Insights

The pipeline for PI3K inhibitors was analyzed based on route of administration, molecule type and phase of drugs. Based on route of administration, around 57.0% active drug candidates are being developed to be administered by oral route, 8.0% by intravenous route and 5.0% to be administered by other routes, including inhalation and intravitreally or subconjunctivally. Most of the drug candidates are being developed to be administered by oral route, due to high patient compliance. Route of administration of around 30.0% active PI3K drug candidates pipeline is not disclosed.

Several companies are targeting PI3K pathways for the treatment of cancer and various other diseases in different phases. The pharmaceutical companies engaged in manufacturing of PI3K inhibitors include, but are not limited to, Novartis Pharmaceuticals, F. Hoffmann-La Roche AG, Verastem, Inc., Bayer AG, GlaxoSmithKline plc, SignalRX Pharmaceuticals Inc., Eli Lilly and Company and PIQUR Therapeutics AG. Novartis AG is developing Buparlisib and Alpelisib, which are Phase III drug candidates.

Positive clinical results from drug candidates targeting PI3K

In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687). The full analysis set comprised of 142 patients, of which 141 patients had iNHL. At the time of analysis, median duration of treatment was 22 weeks and 46 patients remained on treatment. In the FL subset of CHRONOS-1 (n=104), copanlisib treatment resulted in an ORR of 58.7%, including a CR of 14.4% and a median median duration of response of more than 52 weeks, or 370 days (range 0-687), with safety being generally consistent. The most common treatment-related adverse events were transient hyperglycemia (all grades: 49%/Grade ≥3: 40%), which did not show severity above Grade 4, and hypertension (all grades: 29%/Grade ≥3: 23%), which did not show severity above Grade 3.

Phase III - Highest stage of development in PI3K inhibitors pipeline

There are eight PI3K inhibitors in the Phase III stage of development. Among them, Alpelisib is a drug candidate of Novartis Pharmaceuticals AG for the treatment of estrogen receptor positive (ER+) breast cancer. It is in Phase II stage for adenocarcinoma lung cancer, squamous cell lung carcinoma, in Phase I/II stage for acute myeloid leukemia and myelodysplastic syndromes. It is also in Phase I stage for head and neck cancer, breast cancer, esophageal squamous cell carcinoma, colorectal cancer, pancreatic neuroendocrine neoplasms, renal cancer and ovarian cancer. The drug candidate targets PI3K alpha isoform and inhibits its action. It is being developed to be administered by oral route.

Major companies collaborate for the development of PI3K inhibitors pipeline

The research found that different companies engaged in manufacturing of PI3K inhibitors are collaborating. One of the collaborations occurred in November 2016 between Verastem, Inc. and Infinity Pharmaceuticals, Inc. Under the terms of the agreement, Verastem, Inc. licensed all exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib. Verastem paid Infinity Pharmaceuticals, Inc. up to $28.0 million in milestones, with positive data from DUO, a Phase III, randomized monotherapy study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia, triggering the first milestone payment, and royalties on net sales.
Some of the key players developing PI3K inhibitors pipeline include Novartis Pharmaceuticals, F. Hoffmann-La Roche AG, SignalRX Pharmaceuticals Inc., Verastem, Inc., Bayer AG, GlaxoSmithKline plc, Eli Lilly and Company and Takeda Pharmaceutical Limited.

PI3K Inhibitors Pipeline Analysis

  • By Phase
    • Phase III
    • Phase II
    • Phase I
    • Pre-Clinical
    • Discovery

Note: In the pipeline analysis, inactive and discontinued products have been excluded.

  • By Route of Administration
    • Oral
    • Not disclosed
    • Intravenous
    • Others
  • By Target
    • PI3K inhibitor
    • PI3K delta inhibitor
    • PI3K alpha inhibitor
    • Others
  • By Company

LATEST PUBLICATIONS BY P&S

  • Ammonium Phosphate Market

    P&S Market Research - Ammonium Phosphate Market report Market Overview Ammonium phosphate is the salt of phosphoric acid and ammonium. Upon reaction between phosphoric acid a... Continue Reading
  • Anal Cancer Therapeutics Pipeline Analysis

    P&S Market Research - Anal Cancer Therapeutics Pipeline Analysis report Anal cancer therapeutic pipeline analysis is expected to increase owing to increasing incidence globally, majorly in older ... Continue Reading
  • Chronic Myelocytic Leukemia Therapeutics Pipeline Analysis

    P&S Market Research - Chronic Myelocytic Leukemia Therapeutics Pipeline Analysis report Chronic myelocytic leukemia therapeutic pipeline analysis is expected to grow rapidly due to the increasing prevalence of t... Continue Reading
  • Ulcerative Colitis Therapeutics Pipeline Analysis

    P&S Market Research - Ulcerative Colitis Pipeline Analysis report Pipeline Overview Ulcerative colitis is a chronic inflammatory disease, which basically affects colonic mucosa. The mai... Continue Reading
  • Hydraulic Press Machine Market

    P&S Market Research - Hydraulic Press Machine Market report Market Overview The global hydraulic press machine market is projected to witness moderate growth at a CAGR of 4.8% dur... Continue Reading

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Address : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment